为解决 CP-CML 患者 T315I 突变难以预测的问题，浙江大学医学院附属第一医院等单位的研究人员开展构建预测列线图的研究。结果显示该列线图预测效果良好，能助医生识别高风险患者，推荐科研读者阅读。 在血液疾病的领域中，慢性髓性白血病（Chronic Myeloid ...

Considerable effort has been made to override the T315I mutation ( Table 1). The ATP-noncompetitive Abl TKI, ON012380, was the first agent that was able to inhibit both wild-type and all imatinib ...

Cite this: Abl Tyrosine Kinase Inhibitors for Overriding Bcr-Abl/T315I: From the Second to Third Generation - Medscape - Sep 01, 2008.